Leinco Technologies

Anti-Human CD19 (Clone HD37) - Purified

Product Code:
 
LEI-C572
Product Group:
 
Primary Antibodies
Host Type:
 
Mouse
Antibody Isotype:
 
IgG1
Antibody Clonality:
 
Monoclonal
Antibody Clone:
 
HD37
Regulatory Status:
 
RUO
Target Species:
 
Human
Applications:
  • Flow Cytometry
  • Immunoprecipitation (IP)
Shipping:
 
Ambient
Storage:
 
For use within 1 month of purchase store at 2-8°C. For long term storage freeze working aliquots at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
 

No additional charges, what you see is what you pay! *

CodeSizePrice
LEI-C572-0.1mg0.1 mg£396.00
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: US.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • References
  • Related Products
  • Show All

Further Information

Antigen Distribution:
CD19 is expressed in the majority of Pro-B cells to mature B cells (during development) and follicular dendritic cells. Plasma cells do not express CD19.
Concentration:
0.1 mg/ml
Conjugate/Tag/Label:
Purified
Format:
This purified monoclonal antibody is formulated in phosphate buffered saline (PBS), 1 mg/ml BSA and 10 mM sodium azide as a preservative.
Formulation:
This purified monoclonal antibody is formulated in phosphate buffered saline (PBS), 1 mg/ml BSA and 10 mM sodium azide as a preservative.
Long Description:
CD19 is a 95 kD transmembrane glycoprotein and member of the Ig superfamily. The antigen serves as an adaptor protein; drawing cytoplasmic signaling proteins to the membrane. It works via the CD19/CD21 complex to decrease the threshold for B cell receptor signaling pathways. Because of its presence on all B cells, CD19 is a biomarker for B lymphocyte development, lymphoma diagnosis and can be utilized as a target for the immunotherapy of lymphoproliferative disorders. Emerging studies indicate that CD19 plays an active role in fueling the growth of these cancers, most notably by stabilizing the concentrations of the MYC oncoprotein, making CD19 an attractive therapeutic target with respect to its downstream signaling.
NCBI Gene:
930
Target:
CD19

References

1. Leukocyte Typing V (1995) Oxford University Press 2. Leukocyte Typing IV (1989) Oxford University Press 3. Leukocyte Typing III (1987) Oxford University Press 4. Leukocyte Typing II Oxford University Press